Streetbeat News

DSKYF

Daiichi Sankyo Co., Ltd.

https://www.daiichisankyo.co.jp/

CEO

Sunao Manabe

Employees

18,434

Industry

Medicinal and Botanical Manufacturing

Open

27.00

Mkt cap

51B

Volume

100

High

27.00

P/E Ratio

35.05

52-wk high

44.64

Low

26.99

Div yield

0.01

52-wk low

24.61

AstraZeneca and Daiichi Sankyo's drug Enhertu has received conditional approval in China for treating certain lung cancer patients, potentially impacting their market presence and revenues.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 8:55 am

AstraZeneca's Phase 3 trial of datopotamab deruxtecan (Dato-DXd) for breast cancer did not achieve statistical significance in overall survival, though it showed improvement in progression-free survival and patient-reported outcomes. The safety profile was consistent with previous analyses. AstraZeneca's stock is down 1.86% in premarket trading.

Portfolio Pulse from Vandana Singh

September 23, 2024 | 11:44 am

AstraZeneca's investigational cancer drug, datopotamab deruxtecan, showed disappointing results in a late-stage lung cancer trial, failing to achieve statistical significance in improving overall survival compared to standard chemotherapy. Despite a numerical improvement in survival, the results did not meet expectations, leading to a decline in AstraZeneca's stock price.

Portfolio Pulse from Vandana Singh

September 10, 2024 | 12:16 pm

Macquarie has identified 10 Asian stocks, including TSMC and SK Hynix, as top buying opportunities amidst global market volatility. These stocks are seen as resilient to recession fears and are expected to rebound strongly.

Portfolio Pulse from Surbhi Jain

August 07, 2024 | 1:16 pm

Merck & Co Inc (NYSE:MRK) reported strong Q2 earnings with revenue and EPS beating estimates, driven by robust Keytruda sales. However, acquisition costs have led to a downward revision in the annual profit forecast. The company also received an FDA Complete Response Letter for a lung cancer drug application with partner Daiichi Sankyo.

Portfolio Pulse from Vandana Singh

July 30, 2024 | 12:45 pm

The FDA has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) of patritumab deruxtecan, a lung cancer drug developed by Daiichi Sankyo and Merck, due to issues at a third-party manufacturing facility. The CRL did not raise concerns about the drug's efficacy or safety. Merck's stock was down 1.04% following the news.

Portfolio Pulse from Vandana Singh

June 27, 2024 | 2:13 pm

This week, several biotech stocks have key catalysts that could significantly impact their stock prices. Arrowhead Pharmaceuticals, Intellia Therapeutics, Merck, Verona Pharma, and X4 Pharmaceuticals are all set to release important data or have critical events. The SPDR S&P Biotech ETF also saw a rise, reflecting the sector's activity.

Portfolio Pulse from Shanthi Rexaline

June 24, 2024 | 8:51 am

Daiichi Sankyo and AstraZeneca's ENHERTU has shown significant progression-free survival benefits in HR positive, HER2 low metastatic breast cancer, according to the DESTINY-Breast06 trial. Additional data from DESTINY-Breast03 and DESTINY-Breast07 trials reinforce ENHERTU as a standard of care in the second-line setting and highlight its potential in the first-line setting.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 6:49 am

AstraZeneca's stock is trading lower due to the TROPION-Lung01 phase 3 trial results, which did not reach statistical significance in overall survival for the entire trial population. However, the drug showed clinically meaningful improvement in a specific subgroup of patients.

Portfolio Pulse from Vandana Singh

May 28, 2024 | 6:32 pm

AstraZeneca reported positive results from a metastatic breast cancer treatment study for Enhertu, showing significant improvement in progression-free survival. Additionally, AstraZeneca's Truqap, in combination with Faslodex, is recommended for approval in the EU for certain breast cancer patients. Daiichi Sankyo, co-developer of Enhertu, also plays a role in these developments.

Portfolio Pulse from Vandana Singh

April 29, 2024 | 1:26 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.